|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
CTLA-4 inhibitor
|
|
gptkbp:approves
|
gptkb:2011
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:nivolumab
|
|
gptkbp:clinical_trial
|
gptkb:Check_Mate_040
gptkb:Check_Mate_067
gptkb:Check_Mate_142
Phase III
monotherapy or combination therapy
|
|
gptkbp:competitors
|
gptkb:Tafinlar
gptkb:Opdivo
gptkb:Keytruda
|
|
gptkbp:contraindication
|
autoimmune diseases
|
|
gptkbp:defense_mechanism
|
common side effect
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:effective_date
|
gptkb:2011
|
|
gptkbp:formulation
|
lyophilized powder
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Yervoy
|
|
gptkbp:indication
|
unresectable or metastatic melanoma
|
|
gptkbp:ingredients
|
gptkb:ipilimumab
|
|
gptkbp:invention
|
2027
|
|
gptkbp:is_monitored_by
|
immune-related events
|
|
gptkbp:is_used_for
|
treatment of melanoma
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:manufacturer
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:pharmacokinetics
|
long half-life
|
|
gptkbp:population
|
adults
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_information_on
|
ASCO guidelines
NCCN guidelines
|
|
gptkbp:receives_funding_from
|
gptkb:NIH
pharmaceutical companies
|
|
gptkbp:research_areas
|
gptkb:vaccine
oncology
clinical pharmacology
|
|
gptkbp:scholarships
|
gptkb:Educational_Institution
support groups
financial assistance programs
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
hepatitis
dermatitis
immune-related adverse events
neuropathy
colitis
endocrinopathies
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:traded_on
|
gptkb:ipilimumab
|
|
gptkbp:treatment
|
with chemotherapy
with targeted therapy
|
|
gptkbp:bfsParent
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:bfsLayer
|
3
|